ReviewCureus2025
Impact of Urate-Lowering Agents on Renal Outcomes in Chronic Kidney Disease: A Systematic Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic kidney disease (CKD) poses a significant global health burden, with hyperuricemia emerging as a potential modifiable risk factor for disease progression. Urate-lowering agents (ULAs) have been hypothesized to preserve renal function by reducing serum uric acid (SUA) levels and mitigating associated pathogenic mechanisms. However, clinical evidence regarding their efficacy remains inconsistent. This systematic review aimed to evaluate the effects of ULAs on renal outcomes in CKD patients by synthesizing evidence from recent placebo-controlled randomized trials. A comprehensive search of PubMed, Scopus, Web of Science, Embase, and ClinicalTrials.gov was conducted to identify randomized controlled trials (RCTs) published between 2020 and 2025. Ten studies met the inclusion criteria, assessing allopurinol, febuxostat, verinurad, and topiroxostat. The risk of bias was evaluated using the Cochrane Risk of Bias 2 (ROB 2) tool (London, United Kingdom). Data were synthesized narratively due to clinical and methodological heterogeneity. Febuxostat demonstrated potential renal benefits, with significant estimated glomerular filtration rate (eGFR) preservation in three studies. Allopurinol showed neutral effects on eGFR decline in large trials. Albuminuria reduction was observed with verinurad plus febuxostat but not with other ULAs. Safety profiles were favorable across studies, with no significant differences in adverse events versus placebo. While febuxostat may slow CKD progression in select populations, evidence for allopurinol and combination therapies remains inconclusive. Heterogeneity in outcomes underscores the need for personalized treatment and further research to identify optimal candidates for ULA therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.